2024/11/28 更新

写真a

オオハラ ユウキ
大原 悠紀
OHARA Yuki
所属
大学院医学系研究科 附属医学教育研究支援センター 特任研究部門 特任助教
職名
特任助教
通称等の別名
Ohara Yuuki
外部リンク

学位 1

  1. 博士(医学) ( 2018年3月   名古屋大学 ) 

研究キーワード 1

  1. 発がん 酸化ストレス 鉄代謝 メタボロミクス トランスクリプトミクス がん微小環境

研究分野 1

  1. ライフサイエンス / 実験病理学

現在の研究課題とSDGs 2

  1. がんの分子・代謝プロファイリング

  2. マイクロ・ナノプラスチックと健康被害

経歴 5

  1. 名古屋大学   大学院医学系研究科 附属医学教育研究支援センター 特任研究部門   特任助教

    2024年6月 - 現在

  2. National Institutes of Health   National Cancer Institute, Laboratory of Human Carcinogenesis   Special volunteer (客員研究員)

    2024年5月 - 現在

      詳細を見る

    国名:アメリカ合衆国

  3. National Institutes of Health   National Cancer Institute, Laboratory of Human Carcinogenesis   Postdoctoral Fellow

    2019年5月 - 2024年4月

      詳細を見る

  4. 国立研究開発法人国立がん研究センター東病院   レジデント

    2018年4月 - 2019年5月

      詳細を見る

  5. 愛知厚生連海南病院   初期臨床研修医

    2012年4月 - 2014年3月

      詳細を見る

学歴 2

  1. 名古屋大学   大学院   医学系研究科

    2014年4月 - 2018年3月

  2. 弘前大学   医学部   医学科

    2006年4月 - 2012年3月

所属学協会 4

  1. American Association for Cancer Research

      詳細を見る

  2. 日本病理学会

      詳細を見る

  3. 日本癌学会

      詳細を見る

  4. 日本酸化ストレス学会

      詳細を見る

委員歴 2

  1. Free Radical Biology and Medicine   Editorial board member  

    2021年 - 現在   

      詳細を見る

  2. Pathology International   Editorial board member  

    2021年 - 2023年   

      詳細を見る

受賞 7

  1. Fellows Award for Research Excellence (FARE) 2025

    2024年7月   National Institutes of Health   ADRA2A promotes the classical/progenitor subtype and reduces disease aggressiveness of pancreatic cancer

     詳細を見る

  2. 日本病理学会学術奨励賞

    2024年3月   日本病理学会   オミクス解析を用いたがんの分子サブタイプと代謝の誘導メカニズムの解明

     詳細を見る

  3. 2024 UJA論文賞 奨励賞

    2024年3月   海外日本人研究者ネットワーク  

     詳細を見る

  4. SFRR Japan Young Investigator Award

    2017年12月   Society for Free Radical Research Asia   Phlebotomy as a preventive measure for crocidolite-induced mesothelioma in male rats

     詳細を見る

  5. 日本病理学会100周年記念病理学研究新人賞

    2017年4月   日本病理学会   悪性中皮腫の新規治療法・予防法の開発

     詳細を見る

  6. ベストプレゼンテーション賞(第9回NAGOYAグローバルリトリート)

    2017年2月   名古屋大学  

     詳細を見る

  7. Society for Free Radical Research Asia travel award

    2016年11月   Society for Free Radical Research Asia   Preclinical use of CTGF-specific monoclonal antibody for the treatment of malignant mesothelioma

     詳細を見る

▼全件表示

 

論文 21

  1. ADRA2A promotes the classical/progenitor subtype and reduces disease aggressiveness of pancreatic cancer 査読有り 国際誌

    Paloma Moreno, Yuuki Ohara, Amanda J Craig, Huaitian Liu, Shouhui Yang, Tiffany H Dorsey, Lin Zhang, Gatikrushna Panigrahi, Helen Cawley, Azadeh Azizian, Jochen Gaedcke, Michael Ghadimi, Nader Hanna, S Perwez Hussain

    Carcinogenesis     2024年8月

     詳細を見る

    担当区分:筆頭著者, 責任著者   掲載種別:研究論文(学術雑誌)   出版者・発行元:Oxford University Press (OUP)  

    Abstract

    Pancreatic ductal adenocarcinoma (PDAC) manifests diverse molecular subtypes, including the classical/progenitor and basal-like/squamous subtypes, with the latter known for its aggressiveness. We employed integrative transcriptome and metabolome analyses to identify potential genes contributing to the molecular subtype differentiation and its metabolic features. Our comprehensive analysis revealed that adrenoceptor alpha 2A (ADRA2A) was downregulated in the basal-like/squamous subtype, suggesting its potential role as a candidate suppressor of this subtype. Reduced ADRA2A expression was significantly associated with a high frequency of lymph node metastasis, higher pathological grade, advanced disease stage, and decreased survival among PDAC patients. In vitro experiments demonstrated that ADRA2A transgene expression and ADRA2A agonist inhibited PDAC cell invasion. Additionally, ADRA2A-high condition downregulated the basal-like/squamous gene expression signature, while upregulating the classical/progenitor gene expression signature in our PDAC patient cohort and PDAC cell lines. Metabolome analysis conducted on the PDAC cohort and cell lines revealed that elevated ADRA2A levels were associated with suppressed amino acid and carnitine/acylcarnitine metabolism, which are characteristic metabolic profiles of the classical/progenitor subtype. Collectively, our findings suggest that heightened ADRA2A expression induces transcriptome and metabolome characteristics indicative of classical/progenitor subtype with decreased disease aggressiveness in PDAC patients. These observations introduce ADRA2A as a candidate for diagnostic and therapeutic targeting in PDAC.

    DOI: 10.1093/carcin/bgae056

    researchmap

  2. ELAPOR1 induces the classical/progenitor subtype and contributes to reduced disease aggressiveness through metabolic reprogramming in pancreatic cancer 国際誌

    Yuuki Ohara, Huaitian Liu, Amanda J. Craig, Shouhui Yang, Paloma Moreno, Tiffany H. Dorsey, Helen Cawley, Azadeh Azizian, Jochen Gaedcke, Michael Ghadimi, Nader Hanna, Stefan Ambs, S. Perwez Hussain

    International Journal of Cancer     2024年4月

     詳細を見る

    掲載種別:研究論文(学術雑誌)   出版者・発行元:Wiley  

    Abstract

    Pancreatic ductal adenocarcinoma (PDAC) is a heterogeneous disease with distinct molecular subtypes described as classical/progenitor and basal‐like/squamous PDAC. We hypothesized that integrative transcriptome and metabolome approaches can identify candidate genes whose inactivation contributes to the development of the aggressive basal‐like/squamous subtype. Using our integrated approach, we identified endosome–lysosome associated apoptosis and autophagy regulator 1 (ELAPOR1/KIAA1324) as a candidate tumor suppressor in both our NCI‐UMD‐German cohort and additional validation cohorts. Diminished ELAPOR1 expression was linked to high histological grade, advanced disease stage, the basal‐like/squamous subtype, and reduced patient survival in PDAC. In vitro experiments demonstrated that ELAPOR1 transgene expression not only inhibited the migration and invasion of PDAC cells but also induced gene expression characteristics associated with the classical/progenitor subtype. Metabolome analysis of patient tumors and PDAC cells revealed a metabolic program associated with both upregulated ELAPOR1 and the classical/progenitor subtype, encompassing upregulated lipogenesis and downregulated amino acid metabolism. 1‐Methylnicotinamide, a known oncometabolite derived from S‐adenosylmethionine, was inversely associated with ELAPOR1 expression and promoted migration and invasion of PDAC cells in vitro. Taken together, our data suggest that enhanced ELAPOR1 expression promotes transcriptome and metabolome characteristics that are indicative of the classical/progenitor subtype, whereas its reduction associates with basal‐like/squamous tumors with increased disease aggressiveness in PDAC patients. These findings position ELAPOR1 as a promising candidate for diagnostic and therapeutic targeting in PDAC.

    DOI: 10.1002/ijc.34960

    researchmap

  3. LMO3 is a suppressor of the basal-like/squamous subtype and reduces disease aggressiveness of pancreatic cancer through glycerol 3-phosphate metabolism 国際誌

    Yuuki Ohara, Amanda J Craig, Huaitian Liu, Shouhui Yang, Paloma Moreno, Tiffany H Dorsey, Helen Cawley, Azadeh Azizian, Jochen Gaedcke, Michael Ghadimi, Nader Hanna, Stefan Ambs, S Perwez Hussain

    Carcinogenesis     2024年2月

     詳細を見る

    掲載種別:研究論文(学術雑誌)  

    DOI: 10.1093/carcin/bgae011

    researchmap

  4. SERPINB3-MYC axis induces the basal-like/squamous subtype and enhances disease progression in pancreatic cancer 国際誌

    Yuuki Ohara, Wei Tang, Huaitian Liu, Shouhui Yang, Tiffany H. Dorsey, Helen Cawley, Paloma Moreno, Raj Chari, Mary R. Guest, Azadeh Azizian, Jochen Gaedcke, Michael Ghadimi, Nader Hanna, Stefan Ambs, S. Perwez Hussain

    Cell Reports     2023年12月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1016/j.celrep.2023.113434

    researchmap

  5. Diabetes-associated breast cancer is molecularly distinct and shows a DNA damage repair deficiency 国際誌

    Gatikrushna Panigrahi, Julián Candia, Tiffany H. Dorsey, Wei Tang, Yuuki Ohara, Jung S. Byun, Tsion Zewdu Minas, Amy Zhang, Anuoluwapo Ajao, Ashley Cellini, Harris G. Yfantis, Amy L. Flis, Dean Mann, Olga Ioffe, Xin W. Wang, Huaitian Liu, Christopher A. Loffredo, Anna Maria Napoles, Stefan Ambs

    JCI Insight     2023年12月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1172/jci.insight.170105

    researchmap

  6. Dysregulation of HNF1B/Clusterin axis enhances disease progression in a highly aggressive subset of pancreatic cancer patients 国際誌

    Shouhui Yang, Wei Tang, Azadeh Azizian, Jochen Gaedcke, Philipp Ströbel, Limin Wang, Helen Cawley, Yuuki Ohara, Paloma Valenzuela, Lin Zhang, Trisha Lal, Sanju Sinha, Eythan Rupin, Nader Hanna, B Michael Ghadimi, S Perwez Hussain

    Carcinogenesis     2022年12月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    <jats:title>Abstract</jats:title>
    <jats:p>Pancreatic ductal adenocarcinoma (PDAC) is a lethal malignancy and is largely refractory to available treatments. Identifying key pathways associated with disease aggressiveness and therapeutic resistance may characterize candidate targets to improve patient outcomes. We used a strategy of examining the tumors from a subset of PDAC patient cohorts with the worst survival to understand the underlying mechanisms of aggressive disease progression and to identify candidate molecular targets with potential therapeutic significance. Non-negative matrix factorization (NMF) clustering, using gene expression profile, revealed three patient subsets. A 142-gene signature specific to the subset with the worst patient survival, predicted prognosis and stratified patients with significantly different survival in the test and validation cohorts. Gene-network and pathway analysis of the 142-gene signature revealed dysregulation of Clusterin (CLU) in the most aggressive patient subset in our patient cohort. Hepatocyte nuclear factor 1 b (HNF1B) positively regulated CLU, and a lower expression of HNF1B and CLU was associated with poor patient survival. Mechanistic and functional analyses revealed that CLU inhibits proliferation, 3D spheroid growth, invasiveness and epithelial-to-mesenchymal transition (EMT) in pancreatic cancer cell lines. Mechanistically, CLU enhanced proteasomal degradation of EMT-regulator, ZEB1. In addition, orthotopic transplant of CLU-expressing pancreatic cancer cells reduced tumor growth in mice. Furthermore, CLU enhanced sensitivity of pancreatic cancer cells representing aggressive patient subset, to the chemotherapeutic drug gemcitabine. Taken together, HNF1B/CLU axis negatively regulates pancreatic cancer progression and may potentially be useful in designing novel strategies to attenuate disease progression in PDAC patients.</jats:p>

    DOI: 10.1093/carcin/bgac092

    researchmap

  7. The interactive role of inflammatory mediators and metabolic reprogramming in pancreatic cancer 国際誌

    Yuuki Ohara, Paloma Valenzuela, S. Perwez Hussain

    Trends in Cancer     2022年5月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:Elsevier {BV}  

    DOI: 10.1016/j.trecan.2022.03.004

    researchmap

  8. Lactic acid promotes PD-1 expression in regulatory T cells in highly glycolytic tumor microenvironments 国際誌

    Shogo Kumagai, Shohei Koyama, Kota Itahashi, Tokiyoshi Tanegashima, Yi-tzu Lin, Yosuke Togashi, Takahiro Kamada, Takuma Irie, Genki Okumura, Hidetoshi Kono, Daisuke Ito, Rika Fujii, Sho Watanabe, Atsuo Sai, Shota Fukuoka, Eri Sugiyama, Go Watanabe, Takuya Owari, Hitomi Nishinakamura, Daisuke Sugiyama, Yuka Maeda, Akihito Kawazoe, Hiroki Yukami, Keigo Chida, Yuuki Ohara, Tatsuya Yoshida, Yuki Shinno, Yuki Takeyasu, Masayuki Shirasawa, Kenta Nakama, Keiju Aokage, Jun Suzuki, Genichiro Ishii, Takeshi Kuwata, Naoya Sakamoto, Masahito Kawazu, Toshihide Ueno, Taisuke Mori, Naoya Yamazaki, Masahiro Tsuboi, Yasushi Yatabe, Takahiro Kinoshita, Toshihiko Doi, Kohei Shitara, Hiroyuki Mano, Hiroyoshi Nishikawa

    Cancer Cell   40 巻 ( 2 ) 頁: 201 - 218.e9   2022年2月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:Elsevier {BV}  

    DOI: 10.1016/j.ccell.2022.01.001

    researchmap

  9. Drug-exposed cancer-associated fibroblasts facilitate gastric cancer cell progression following chemotherapy 国際誌

    Takahiro Ishii, Ayako Suzuki, Takeshi Kuwata, Shoshi Hisamitsu, Hiroko Hashimoto, Yuuki Ohara, Kazuyoshi Yanagihara, Shuichi Mitsunaga, Takayuki Yoshino, Takahiro Kinoshita, Atsushi Ochiai, Kohei Shitara, Genichiro Ishii

    Gastric Cancer   24 巻 ( 4 ) 頁: 810 - 822   2021年7月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:Springer Science and Business Media {LLC}  

    DOI: 10.1007/s10120-021-01174-9

    researchmap

  10. The critical role of CD4+ T cells in PD-1 blockade against MHC-II–expressing tumors such as classic Hodgkin lymphoma 国際誌

    Joji Nagasaki, Yosuke Togashi, Takeaki Sugawara, Makiko Itami, Nobuhiko Yamauchi, Junichiro Yuda, Masato Sugano, Yuuki Ohara, Yosuke Minami, Hirohisa Nakamae, Masayuki Hino, Masahiro Takeuchi, Hiroyoshi Nishikawa

    Blood Advances   4 巻 ( 17 ) 頁: 4069 - 4082   2020年9月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:American Society of Hematology  

    <jats:title>Abstract</jats:title>
    <jats:p>Classic Hodgkin lymphoma (cHL) responds markedly to PD-1 blockade therapy, and the clinical responses are reportedly dependent on expression of major histocompatibility complex class II (MHC-II). This dependence is different from other solid tumors, in which the MHC class I (MHC-I)/CD8+ T-cell axis plays a critical role. In this study, we investigated the role of the MHC-II/CD4+ T-cell axis in the antitumor effect of PD-1 blockade on cHL. In cHL, MHC-I expression was frequently lost, but MHC-II expression was maintained. CD4+ T cells highly infiltrated the tumor microenvironment of MHC-II–expressing cHL, regardless of MHC-I expression status. Consequently, CD4+ T-cell, but not CD8+ T-cell, infiltration was a good prognostic factor in cHL, and PD-1 blockade showed antitumor efficacy against MHC-II–expressing cHL associated with CD4+ T-cell infiltration. Murine lymphoma and solid tumor models revealed the critical role of antitumor effects mediated by CD4+ T cells: an anti-PD-1 monoclonal antibody exerted antitumor effects on MHC-I−MHC-II+ tumors but not on MHC-I−MHC-II− tumors, in a cytotoxic CD4+ T-cell–dependent manner. Furthermore, LAG-3, which reportedly binds to MHC-II, was highly expressed by tumor-infiltrating CD4+ T cells in MHC-II–expressing tumors. Therefore, the combination of LAG-3 blockade with PD-1 blockade showed a far stronger antitumor immunity compared with either treatment alone. We propose that PD-1 blockade therapies have antitumor effects on MHC-II–expressing tumors such as cHL that are mediated by cytotoxic CD4+ T cells and that LAG-3 could be a candidate for combination therapy with PD-1 blockade.</jats:p>

    DOI: 10.1182/bloodadvances.2020002098

    researchmap

  11. Connective tissue growth factor produced by cancer‑associated fibroblasts correlates with poor prognosis in epithelioid malignant pleural mesothelioma 国際誌

    Yuuki Ohara, Atsushi Enomoto, Yuta Tsuyuki, Kotaro Sato, Tadashi Iida, Hiroki Kobayashi, Yasuyuki Mizutani, Yuki Miyai, Akitoshi Hara, Shinji Mii, Jun Suzuki, Kyoko Yamashita, Fumiya Ito, Yashiro Motooka, Nobuaki Misawa, Takayuki Fukui, Koji Kawaguchi, Kohei Yokoi, Shinya Toyokuni

    Oncology Reports   44 巻 ( 3 ) 頁: 838 - 848   2020年7月

     詳細を見る

    掲載種別:研究論文(学術雑誌)   出版者・発行元:Spandidos Publications  

    DOI: 10.3892/or.2020.7669

    researchmap

  12. Clinicopathological characteristics associated with necrosis in pulmonary metastases from colorectal cancer 国際誌

    Jun Suzuki, Motohiro Kojima, Keiju Aokage, Takashi Sakai, Hiroshi Nakamura, Yuuki Ohara, Kenta Tane, Tomohiro Miyoshi, Masato Sugano, Satoshi Fujii, Takeshi Kuwata, Atsushi Ochiai, Masaaki Ito, Kenji Suzuki, Masahiro Tsuboi, Genichiro Ishii

    Virchows Archiv   474 巻 ( 5 ) 頁: 569 - 575   2019年2月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:Springer Science and Business Media LLC  

    DOI: 10.1007/s00428-019-02535-7

    researchmap

    その他リンク: http://link.springer.com/content/pdf/10.1007/s00428-019-02535-7.pdf

  13. Non-thermal plasma specifically kills oral squamous cell carcinoma cells in a catalytic Fe(II)-dependent manner 国際誌

    Kotaro Sato, Lei Shi, Fumiya Ito, Yuuki Ohara, Yashiro Motooka, Hiromasa Tanaka, Masaaki Mizuno, Masaru Hori, Tasuku Hirayama, Hideharu Hibi, Shinya Toyokuni

    Journal of Clinical Biochemistry and Nutrition   65 巻 ( 1 ) 頁: 8 - 15   2019年

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:The Society for Free Radical Research Japan  

    DOI: 10.3164/jcbn.18-91

    researchmap

  14. Acute fulminant invasive pulmonary aspergillosis in an immunocompetent host: An autopsy case report 国際誌

    Yuuki Ohara, Takahiko Ito, Makoto Ito, Kyoko Yamashita, Shinya Toyokuni

    Medical Mycology Case Reports   20 巻   頁: 39 - 42   2018年6月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:Elsevier BV  

    DOI: 10.1016/j.mmcr.2018.02.002

    researchmap

  15. Connective tissue growth factor-specific monoclonal antibody inhibits growth of malignant mesothelioma in an orthotopic mouse model 国際誌

    Yuuki Ohara, Shan Hwu Chew, Nobuaki Misawa, Shenqi Wang, Daiki Somiya, Kae Nakamura, Hiroaki Kajiyama, Fumitaka Kikkawa, Yuta Tsuyuki, Li Jiang, Kyoko Yamashita, Yoshitaka Sekido, Kenneth E. Lipson, Shinya Toyokuni

    Oncotarget   9 巻 ( 26 ) 頁: 18494 - 18509   2018年4月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:Impact Journals, LLC  

    DOI: 10.18632/oncotarget.24892

    researchmap

  16. An autopsy case report: Differences in radiological images correlate with histology in Erdheim–Chester disease 国際誌

    Yuuki Ohara, Seiichi Kato, Daisuke Yamashita, Akira Satou, Yoshie Shimoyama, Chie Hamaie, Motoki Sato, Nobutaro Ban, Koji Yamamoto, Takehiro Yamada, Hisashi Kawai, Koichi Ohshima, Shigeo Nakamura, Shinya Toyokuni

    Pathology International   68 巻 ( 6 ) 頁: 374 - 381   2018年3月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:Wiley  

    p16 activation caused by oncogenic mutations may represent oncogene‐induced senescence (OIS), a protective mechanism against oncogenic events. However, OIS can contribute to tumor development via tissue remodeling in some tumors. Erdheim–Chester disease (ECD), a rare non‐Langerhans cell histiocytosis, is one such tumor. Its clinical and histological features vary, making it difficult to diagnose. Herein, we describe an autopsy of an ECD patient. The patient underwent radiological examinations, including <sup>18</sup>F‐fluorodeoxyglucose (FDG)‐positron emission tomography/computed tomography (PET/CT), bone scintigraphy and CT. A biopsy from the lesion with the highest FDG accumulation confirmed the presence of foamy macrophages, a diagnostic clue for ECD. Based on this finding and the clinical features, ECD was diagnosed. However, the patient died from heart dysfunction. After the autopsy, each radiologically different site showed various histological findings regarding the morphology of macrophages, fibrosis, inflammation, and p16 expression. OIS‐induced histological progression can cause certain changes observed in radiological images. In addition, in order to evaluate the increase in glucose metabolism, which can affect FDG accumulation, the expression of glucose transporter 1 and hexokinase II was also analyzed. Summarizing the radio‐histological correlation can help further both the understanding and diagnosis of ECD.

    DOI: 10.1111/pin.12663

    researchmap

  17. Phlebotomy as a preventive measure for crocidolite‐induced mesothelioma in male rats 国際誌

    Yuuki Ohara, Shan‐Hwu Chew, Takahiro Shibata, Yasumasa Okazaki, Kyoko Yamashita, Shinya Toyokuni

    Cancer Science   109 巻 ( 2 ) 頁: 330 - 339   2018年1月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:Wiley  

    Malignant mesothelioma (MM) is a rare but socially important neoplasm due to its association with asbestos exposure. Malignant mesothelioma is difficult to diagnose at an early stage, yet there are no particularly effective treatments available at the advanced stage, thus necessitating efficient strategies to prevent MM in individuals already exposed to asbestos. We previously showed that persistent oxidative damage caused by foreign body reaction and affinity of asbestos both to hemoglobin and histones is one of the major pathogeneses. Accordingly, as an effective strategy to prevent asbestos‐induced MM, we undertook the use of an iron chelator, deferasirox, which decreased the epithelial–mesenchymal transition in a crocidolite‐induced rat MM model. However, this agent may show adverse effects. Here, we studied the effects of iron removal by phlebotomy as a realistic measure on the same rat model. We injected a total of 5 mg crocidolite i.p. to F1 hybrid rats between the Fischer‐344 and Brown‐Norway strains at the age of 6 weeks. We repeated weekly or biweekly phlebotomy of 6‐8 mL/kg/time from 10 to 60 weeks of age. The animals were observed until 120 weeks. In male rats, phlebotomy significantly decreased the weight and nuclear grade of MM, and modestly reduced the associated ascites and the fraction of more malignant sarcomatoid subtype. Weekly phlebotomy prolonged long‐term survival. Our results indicate that appropriate phlebotomy may be a practical preventive measure to attenuate the initiation and promotion capacity of asbestos towards MM by reducing iron in individuals exposed to asbestos.

    DOI: 10.1111/cas.13460

    researchmap

  18. Osteogenic differentiation in dedifferentiated liposarcoma: a study of 36 cases in comparison to the cases without ossification 国際誌

    Kyoko Yamashita, Kenichi Kohashi, Yuichi Yamada, Takeaki Ishii, Yoshihiro Nishida, Hiroshi Urakawa, Ichiro Ito, Mitsuru Takahashi, Takeshi Inoue, Masafumi Ito, Yuuki Ohara, Yoshinao Oda, Shinya Toyokuni

    Histopathology   72 巻 ( 5 ) 頁: 729 - 738   2017年12月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:Wiley  

    Aims

    Ossification is found occasionally in dedifferentiated liposarcoma (DDLPS). The aims of this study were to elucidate whether the formed bone tissue is usually produced by tumour cells or by reactive non‐neoplastic cells, and to reveal the clinicopathological characteristics of DDLPS with ossification.

    Methods and results

    We examined 36 cases of ossified DDLPS by comparing them to 31 cases of non‐ossified DDLPS. MDM2 amplification was confirmed in osteocytes and/or osteoblastic cells in all but one ossified DDLPS cases (27 of 28) using fluorescence in‐situ hybridisation, although the morphological impression of ossification appeared to be mainly metaplastic (27 of 36) or high‐grade osteosarcoma‐like (six of 36). The bone tissue was often formed predominantly at the periphery of the DDLPS area near the well‐differentiated liposarcoma component (18 of 36), and an organised structure such as bone marrow‐like differentiation was not uncommon (12 of 36). According to a modified French Fédération Nationale des Centers de Lutte Contre le Cancer (FNCLCC) grading system, ossified DDLPS tended to be lower grade than non‐ossified DDLPS (mean grade: 1.88 and 2.15, respectively). Ossification in DDLPS was associated significantly with shorter local recurrence‐free survival by multivariate analysis (P = 0.02347), but metaplastic‐appearing ossification tended to be associated with longer overall survival (P = 0.1400).

    Conclusions

    The bone tissue formed in DDLPS was mainly neoplastic regardless of its morphology and maturity, which highlighted the osteogenic differentiation of the tumour cells. DDLPS patients with osteogenic differentiation tended to suffer from earlier local recurrences, which did not necessarily lead to poor life outcomes.

    DOI: 10.1111/his.13421

    researchmap

  19. Rheostatic CD44 isoform expression and its association with oxidative stress in human malignant mesothelioma 国際誌

    Shan Hwu Chew, Yasumasa Okazaki, Shinya Akatsuka, Shenqi Wang, Li Jiang, Yuuki Ohara, Fumiya Ito, Hideyuki Saya, Yoshitaka Sekido, Shinya Toyokuni

    Free Radical Biology and Medicine   106 巻   頁: 91 - 99   2017年5月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:Elsevier BV  

    DOI: 10.1016/j.freeradbiomed.2017.02.011

    researchmap

  20. Urokinase-type plasminogen activator receptor promotes proliferation and invasion with reduced cisplatin sensitivity in malignant mesothelioma 国際誌

    Shenqi Wang, Li Jiang, Yipeng Han, Shan Hwu Chew, Yuuki Ohara, Shinya Akatsuka, Liang Weng, Koji Kawaguchi, Takayuki Fukui, Yoshitaka Sekido, Kohei Yokoi, Shinya Toyokuni

    Oncotarget   7 巻 ( 43 ) 頁: 69565 - 69578   2016年9月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:Impact Journals, LLC  

    DOI: 10.18632/oncotarget.11829

    researchmap

  21. Dual preventive benefits of iron elimination by desferal in asbestos‐induced mesothelial carcinogenesis 国際誌

    Li Jiang, Shan‐Hwu Chew, Kosuke Nakamura, Yuuki Ohara, Shinya Akatsuka, Shinya Toyokuni

    Cancer Science   107 巻 ( 7 ) 頁: 908 - 915   2016年6月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:Wiley  

    Asbestos‐induced mesothelial carcinogenesis is currently a profound social issue due to its extremely long incubation period and high mortality rate. Therefore, procedures to prevent malignant mesothelioma in people already exposed to asbestos are important. In previous experiments, we established an asbestos‐induced rat peritoneal mesothelioma model, which revealed that local iron overload is a major cause of pathogenesis and that the induced genetic alterations are similar to human counterparts. Furthermore, we showed that oral administration of deferasirox modified the histology from sarcomatoid to the more favorable epithelioid subtype. Here, we used i.p. administration of desferal to evaluate its effects on asbestos‐induced peritoneal inflammation and iron deposition, as well as oxidative stress. Nitrilotriacetate was used to promote an iron‐catalyzed Fenton reaction as a positive control. Desferal significantly decreased peritoneal fibrosis, iron deposition, and nuclear 8‐hydroxy‐2′‐deoxyguanosine levels in mesothelial cells, whereas nitrilotriacetate significantly increased all of them. Desferal was more effective in rat peritoneal mesothelial cells to counteract asbestos‐induced cytotoxicity than in murine macrophages (RAW264.7). Furthermore, rat sarcomatoid mesothelioma cells were more dependent on iron for proliferation than rat peritoneal mesothelial cells. Because inflammogenicity of a fiber is proportionally associated with subsequent mesothelial carcinogenesis, iron elimination from the mesothelial environment can confer dual merits for preventing asbestos‐induced mesothelial carcinogenesis by suppressing inflammation and mesothelial proliferation simultaneously.

    DOI: 10.1111/cas.12947

    researchmap

    その他リンク: https://onlinelibrary.wiley.com/doi/full-xml/10.1111/cas.12947

▼全件表示

書籍等出版物 2

  1. 免疫チェックポイント阻害によるがん治療 (特集 抗体医薬・生物学的製剤療法の現状と課題)

    大原 悠紀, 西川 博嘉

    科学評論社 臨床免疫・アレルギー科72(3), 276-282, 2019  2019年 

     詳細を見る

  2. ロビンス基礎病理学 原書10版

    監訳 豊國伸哉, 高橋雅英( 担当: 共訳 ,  範囲: 第11章 心臓)

    丸善出版 エルゼビア ジャパン  2018年1月 

     詳細を見る

MISC 4

  1. びまん性胸膜肥厚を伴う肺炎の一剖検例

    佐々木 香菜子, 岡崎 泰昌, 大原 悠紀, 豊國 伸哉  

    日本病理学会会誌107 巻 ( 1 ) 頁: 529 - 529   2018年4月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本病理学会  

    researchmap

  2. ラットモデルにおいて瀉血は悪性中皮腫の増殖を抑制する(Phlebotomy attenuates the growth of malignant mesothelioma on rat model)

    大原 悠紀, 宗宮 大輝, 柴田 崇宏, 豊國 伸哉  

    日本病理学会会誌106 巻 ( 1 ) 頁: 410 - 410   2017年3月

     詳細を見る

    記述言語:英語   出版者・発行元:(一社)日本病理学会  

    researchmap

  3. 巨大な脱分化型脂肪肉腫の一剖検例

    尾崎 航太郎, 大原 悠紀, 亀山 祐行, 山下 享子, 豊國 伸哉  

    日本病理学会会誌105 巻 ( 1 ) 頁: 582 - 582   2016年4月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本病理学会  

    researchmap

  4. 線維芽細胞はConnective tissue growth factorを介して悪性中皮腫細胞増殖を促進する

    宗宮 大輝, 大原 悠紀, 豊國 伸哉  

    日本病理学会会誌105 巻 ( 1 ) 頁: 590 - 591   2016年4月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本病理学会  

    researchmap

共同研究・競争的資金等の研究課題 2

  1. 悪性中皮腫の発症・進展を制御する癌関連線維芽細胞の役割の解明

    2017年1月 - 2017年12月

    一般社団法人 名古屋大学医師会  平成28年度 研究助成 

      詳細を見る

    担当区分:研究代表者 

  2. 悪性中皮腫の病態、予防、新規治療に関する研究

    2014年4月 - 2018年3月

    公益財団法人武田科学振興財団  医学部博士課程奨学助成 

科研費 1

  1. オミクス解析を用いたSERPINB3が誘導する膵臓がん間質の分子・代謝サブタイプの解明

    研究課題/研究課題番号:24K23378  2024年7月 - 2026年3月

    日本学術振興会  科学研究費助成事業  研究活動スタート支援

    大原 悠紀

      詳細を見る

 

担当経験のある科目 (本学) 4

  1. 基礎セミナー

    2024

  2. 基礎医学セミナー

    2024

  3. 基礎医学セミナー

    2015

     詳細を見る

    基礎医学セミナーで学部3年生を担当し、中皮腫の線維芽細胞におけるConnective tissue growth factorの役割についての研究を4ケ月間指導した。

  4. 基礎医学セミナー

    2014

     詳細を見る

    基礎医学セミナーで学部3年生を担当し、中皮腫におけるConnective tissue growth factorの役割についての研究を4か月間指導した。